DYRK2 aberrations have been reported in the development and progression of several human carcinomas, such as esophageal adenocarcinoma, breast cancer, non‐small cell lung cancer, ovarian serous adenocarcinoma, etc. DYRK2 has been shown to limit epithelial‐mesenchymal transition (EMT) by degrading Snail in ovarian cancer and its knockdown promotes tumor growth and invasion, thereby attesting its role as a tumor suppressor. Here, DYRK2 is linked to breast cancer.